Quote:

---

With EUA on the S/C population, we aren't going to blast off to $15-20 or anything

---

Price will be based on perceived revenue but more importantly on broader awareness. The small group of current investors has some idea of what leronlimab can do. Most investors don't know we exist and those that do and have done light due diligence are doubtful of the potential. Once the broader investment community figures out the potential across a host of diseases, $15-$20 should be achievable.